Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) Sponsor: University of Oxford The study is a double-blind, randomi

Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) Sponsor: University of Oxford The study is a double-blind, randomised, placebo-controlled trial that will be conducted in health care settings. After obtaining fully informed consent, the investigator will recruit healthcare workers, or other individuals at significant risk who can be followed reliably for 5 months. 10,000 participants will be recruited and the investigator predict an average of 200 participants per site in 50 sites. https://clinicaltrials.gov/ct2/show/NCT04303507 https://clinicaltrials.gov/ct2/show/NCT04303507 UK bans parallel export and hoarding of three Covid-19 drugs By GlobalData Healthcare SHARE The UK government has banned the parallel export and “hoarding” of three drugs being used to treat coronavirus patients in China in anticipation of shortages in Britain following the Covid-19 pandemic. The export of the US-based AbbVie’s Kaletra / Aluvia, a combination lopinavir and ritonavir, the generic drug chloroquine phosphate and the generic drug hydroxychloroquine is being restricted to meet the needs of UK patients, the government said. Hydroxychloroquine was placed on the restricted list from 14 March and Kaletra and chloroquine phosphate were added on 26 February. https://www.pharmaceutical-technology.com/comment/parallel-export-covid-19/ https://www.pharmaceutical-technology.com/comment/parallel-e...